These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 11597826

  • 1. Urocortin protects against ischemic injury via a MAPK-dependent pathway.
    Latchman DS.
    Trends Cardiovasc Med; 2001 Jul; 11(5):167-9. PubMed ID: 11597826
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes.
    Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS.
    J Mol Cell Cardiol; 2003 Oct; 35(10):1295-305. PubMed ID: 14519439
    [Abstract] [Full Text] [Related]

  • 5. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death.
    Brar BK, Stephanou A, Knight R, Latchman DS.
    J Mol Cell Cardiol; 2002 Apr; 34(4):483-92. PubMed ID: 11991736
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.
    Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH.
    Proc Natl Acad Sci U S A; 2013 Oct 01; 110(40):16133-8. PubMed ID: 24043794
    [Abstract] [Full Text] [Related]

  • 10. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes.
    Railson JE, Liao Z, Brar BK, Buddle JC, Pennica D, Stephanou A, Latchman DS.
    Cytokine; 2002 Mar 07; 17(5):243-53. PubMed ID: 12027405
    [Abstract] [Full Text] [Related]

  • 11. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.
    Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW.
    Mol Endocrinol; 2000 Dec 07; 14(12):2076-91. PubMed ID: 11117536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.
    Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, Szücs A, Koob GF, Zorrilla EP.
    Neuropsychopharmacology; 2007 May 07; 32(5):1052-68. PubMed ID: 17019404
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I.
    Pedersen WA, Wan R, Zhang P, Mattson MP.
    J Neurosci; 2002 Jan 15; 22(2):404-12. PubMed ID: 11784785
    [Abstract] [Full Text] [Related]

  • 19. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK.
    Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM.
    J Cardiovasc Pharmacol; 2001 Dec 15; 38(6):930-9. PubMed ID: 11707697
    [Abstract] [Full Text] [Related]

  • 20. Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility.
    Karteris E, Hillhouse EW, Grammatopoulos D.
    Endocrinology; 2004 Feb 15; 145(2):890-900. PubMed ID: 14592950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.